210,550 Shares in Intellia Therapeutics, Inc. $NTLA Bought by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 2nd quarter, Holdings Channel reports. The fund acquired 210,550 shares of the company’s stock, valued at approximately $3,563,000.

Other large investors have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Intellia Therapeutics in the second quarter valued at about $363,000. Bank of New York Mellon Corp bought a new position in shares of Intellia Therapeutics during the second quarter worth about $6,948,000. State of Wyoming bought a new position in shares of Intellia Therapeutics during the second quarter worth about $51,000. GSA Capital Partners LLP acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at approximately $234,000. Finally, Hennion & Walsh Asset Management Inc. raised its position in Intellia Therapeutics by 38.0% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 220,523 shares of the company’s stock valued at $3,731,000 after buying an additional 60,720 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 2.4%

NASDAQ:NTLA opened at $13.19 on Thursday. Intellia Therapeutics, Inc. has a twelve month low of $7.95 and a twelve month high of $28.25. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -3.93 and a beta of 1.81. The stock’s 50 day moving average price is $13.36 and its two-hundred day moving average price is $13.37.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The company had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. During the same quarter in the prior year, the firm posted ($0.98) EPS. The firm’s revenue for the quarter was down 46.4% compared to the same quarter last year. As a group, analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 15th. Evercore raised shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective on the stock in a research report on Friday, August 7th. Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. Finally, Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and an average price target of $21.15.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.50% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.